Content Sponsored by Sanofi

This Sanofi Deskside Series presentation discusses the impact of autologous hematopoietic cell transplantation (HCT) and quadruplet induction therapy compared to a triplet regimen in the CASSIOPEIA and GRIFFIN Trials in transplant-eligible patients with newly diagnosed multiple myeloma.

Visit to learn more about why early consultation for autologous HCT is important for patients with multiple myeloma.

© 2021 sanofi-aventis U.S. LLC. All rights reserved. MAT-US-2106329-v1.0-07/2021